Mixed Cues: Bagga Recommends Pharma, Defence; Cautions on IT Stocks

Ajay Bagga, a market expert, has outlined a sector-specific investment strategy for 2026, advising investors to be cautious on the IT sector until tangible AI revenue materializes. Conversely, he has given a strong buy recommendation for the pharmaceutical and defence sectors, citing their inherent advantages and growth potential.

This guidance is significant for Indian equity traders as it suggests a potential rotation of capital out of the IT sector and into defensive and growth-oriented sectors like pharma and defence. Such expert opinions can influence retail and institutional investor sentiment, leading to sector-specific movements in the near to medium term.

The IT sector, including major players like TCS, INFY, WIPRO, and HCLTECH, could face negative sentiment and potential outflows. Conversely, pharmaceutical stocks such as SUNPHARMA, DRREDDY, LUPIN, and DIVISLAB, along with defence-related companies like HAL, BEL, and Mazagon Dock (MAZDAOCK), could see increased buying interest and positive price action.

Traders should monitor the performance of IT stocks for any signs of AI-driven revenue growth or further weakness. For pharma and defence, watch for sustained buying interest and any specific policy announcements or order wins that could act as catalysts. Also, observe FII/DII flows into these sectors for confirmation of the suggested rotation.

• •Ajay Bagga advises waiting for real AI revenue in the IT sector.
• •Pharma is recommended as a strong investment due to multiple advantages.
• •Defence is highlighted as a long-term play with significant growth potential.
• •Bagga specifically mentions shipbuilders and drone makers within the defence sector.
• •Risk flag: USFDA/regulatory hurdles for pharma companies